Up-regulation of Secretoneurin Immunoreactivity and Secretogranin II Mrna in Rat Striatum Following 6-Hydroxydopamine Lesioning and Chronic L-DOPA Treatment.
Neuroscience(2001)SCI 3区
GlaxoSmithKline | Neurodegenerative Diseases Research Centre | Neuroscience Research
Abstract
Destruction of the nigro-striatal pathway in Parkinson's disease and treatment with L-DOPA lead to persistent alterations in basal ganglia output pathways that are poorly characterised. Differential display mRNA analysis was used to study the effects of 6-hydroxydopamine-induced lesions of the medial forebrain bundle on gene expression in the rat striatum. One up-regulated cDNA identified in two independent groups of 6-hydroxydopamine-lesioned animals was cloned and sequence analysis showed 97% homology to secretogranin II. Differential up-regulation of secretogranin II following 6-hydroxydopamine lesioning was confirmed in a further group of 6-hydroxydopamine-lesioned rats using TaqMan real time quantitative reverse transcription-polymerase chain reaction. Following chronic L-DOPA treatment of 6-hydroxydopamine-lesioned rats, secretogranin II mRNA was further up-regulated to a similar degree to that observed for preproenkephalin A mRNA expression. Immunohistochemical analysis confirmed the increase in secretogranin II peptide levels in striatal neurones in 6-hydroxydopamine-lesioned rats following chronic L-DOPA treatment. The increase in secretogranin II mRNA occurring following destruction of the nigro-striatal pathway and chronic L-DOPA treatment may result in an increase in secretoneurin levels, which could be important for the regulation of striatal output pathways.
MoreTranslated text
Key words
nigral-striatal pathway,differential display,up-regulation,TaqMan,gene expression
求助PDF
上传PDF
View via Publisher
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
- Pretraining has recently greatly promoted the development of natural language processing (NLP)
- We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
- We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
- The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
- Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Related Papers
Striatal Dendritic Adaptations in Parkinson’s Disease Models
Cortico-Subcortical Dynamics in Parkinson¿s Disease 2008
被引用0
Expression Profiling to Understand Actions of NMDA/Glutamate Receptor Antagonists in Rat Brain
Neurochemical Research 2002
被引用11
Functional Genomics in Neuropsychiatric Disorders and in Neuropharmacology.
Expert opinion on therapeutic targets 2002
被引用3
Target Identification for CNS Diseases by Transcriptional Profiling
Neuropsychopharmacology 2009
被引用139
The FASEB Journal 2007
被引用64
Monocular Enucleation Profoundly Reduces Secretogranin Ii Expression in Adult Mouse Visual Cortex
NEUROCHEMISTRY INTERNATIONAL 2011
被引用5
Neuropharmacological studies of Parkinson´s disease with some emphasis on serotonin transmission
2008
被引用23
Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: Cdna Microarray Studies
Oxidative Stress and Neurodegenerative Disorders 2007
被引用13
Nöro Psikiyatri Arşivi 2017
被引用1
npj Parkinson s Disease 2024
被引用0
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper
Summary is being generated by the instructions you defined